According to the amyloid hypothesis, β-secretase (BACE1; β-site amyloid precursor protein cleaving enzyme 1), an enzyme triggering the formation of the Aβ peptide, is a key drug target to be exploited for the development of novel anti-AD drugs [3]. This evidence concerns the gene BACE1 and Alzheimer disease.